Prediction of Outcomes With a Miniaturized Transesophageal Echocardiography Probe in Patients With Acute Respiratory Distress Syndrome (PreMiTE-ARDS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The Superior Vena cava Respiratory Collapse Index (cVCS) is a haemodynamic parameter measured exclusively by transoesophageal ultrasound (TEE), which is used to assess cardiac precharge-dependence status. This may be an important prognostic factor in ARDS because it is a sign of hypervolemia and right heart failure.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients with mechanical ventilation hospitalized in intensive care, emergency or intensive care units
Patients hospitalized in Resuscitation, Emergency or Intensive Care Units at the Roger Salengro Hospital at Lille University Hospital.
With acute respiratory distress syndrome of intermediate or severe severity (1) for less than 24 hours.
Mechanical ventilation with tracheal intubation or tracheostomy, in controlled assisted ventilation (VAC) mode.
Patient adapted to mechanical ventilation (no triggering of spontaneous ventilation cycle in VAC mode verified by the equality between the respiratory rate prescribed on the ventilator and the actual respiratory rate of the patient).
Patient under extracorporeal respiratory assistance at the time of inclusion.
Anomalies or pathologies that make it dangerous or impossible to introduce an ETO probe:
Fistula, perforation, stenosis, varicose vein or diverticulum of the esophagus and / or stomach
History of esophageal and / or gastric surgery
Caustic lesions of the esophagus and / stomach
Tumor or history of oropharyngeal surgery
Unstable lesions of the cervical spine
Coagulopathy (thrombocytopenia <50 109 / L and / or TP <50%).
Impossibility of measuring the diameter of the superior vena cava and cVCS in ETO due to poor echogenicity.
Therapeutic limitation measures limiting the treatment of organ failure.